Research programme: uroguanylin-based nanotherapeutics - Pfizer/Synergy Pharmaceuticals

Drug Profile

Research programme: uroguanylin-based nanotherapeutics - Pfizer/Synergy Pharmaceuticals

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BIND Therapeutics; Synergy Pharmaceuticals Inc
  • Developer Pfizer; Synergy Pharmaceuticals Inc
  • Class Antineoplastics
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal cancer

Most Recent Events

  • 15 Mar 2016 Preclinical trials in Gastrointestinal cancer in USA (unspecified route) before March 2016
  • 16 Feb 2016 BIND Therapeutics and Synergy Pharmaceuticals agree to co-develop uroguanylin-based nanotherapeutics in USA for Gastrointestinal cancer
  • 16 Feb 2016 Early research in Gastrointestinal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top